A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Experimental: L-SABR Arm

Participants randomized to the experimental arm will continue with standard of care treatment but will also undergo radiation simulation for L-SABR/Liver Stereotactic Ablative Radiation Therapy.

Radiation: L-SABR

L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.

Other Name: Liver Stereotactic Ablative Radiation Therapy

Biological: Anti-PD-(L)1 based immunotherapy

Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

Other Name: Standard of Care

Drug: Platinum based chemotherapy

Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy

Other Name: Standard of Care

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 21, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments